Clinical research
South San Francisco-based Allogene Therapeutics released some early data from its Phase I UNIVERSAL clinical trial of ALLO-715 for relapsed/refractory multiple myeloma.
Aptevo is a clinical-stage biotech company developing novel therapeutics built on its proprietary platform ADAPTIR™technology which is modular and includes bispecific molecules that recognize and bind to two unique target antigens simultaneously.
Additional findings from Biogen’s Phase II LILAC study, announced today, show the company’s lupus drug candidate BIIB059 is superior to placebo for reducing joint disease activity in patients with systemic lupus erythematosus.
The company announced positive topline results in its Phase III study of Xpovio (selinexor) in patients with advanced unresectable dedifferentiated liposarcoma, which sets up potential approval in this indication.
Three biopharma companies recently shuttered their clinical programs after either their compounds failed clinical trials or interim futility analysis suggested they were unlikely to meet their clinical endpoints. Here’s a look.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for November 3, 2020.
GW Pharmaceuticals hopes to bring its cannabis-based treatment nabiximols for multiple sclerosis spasticity to the United States.
“With limited oral therapeutic options available for psoriasis, there remains a significant need for safe and effective therapies,” said April Armstrong, associate dean and professor of dermatology at the University of Southern California.
Regeneron announced on Friday that it is pausing dosing of garetosmab (REGN2477), an investigational therapy, in the Phase I LUMINA-1 trial.
Newly announced results of a Phase I dose-escalation study show CureVac’s COVID-19 vaccine candidate, CVnCoV, generates noticeable immune responses in healthy volunteers.
PRESS RELEASES